BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37334575)

  • 21. Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism.
    Zhu J; Petit PF; Van den Eynde BJ
    Cancer Immunol Immunother; 2019 May; 68(5):835-847. PubMed ID: 30406374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors.
    Herrnring C; Reimer T; Jeschke U; Makovitzky J; Krüger K; Gerber B; Kabelitz D; Friese K
    Histochem Cell Biol; 2000 Mar; 113(3):189-94. PubMed ID: 10817673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC).
    Fukuzawa Y; Takahashi K; Furuta K; Tagaya T; Ishikawa T; Wada K; Omoto Y; Koji T; Kakumu S
    J Gastroenterol; 2001 Oct; 36(10):681-8. PubMed ID: 11686478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
    Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
    J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fas ligand promotes tumor immune evasion of colon cancer in vivo.
    Ryan AE; Shanahan F; O'Connell J; Houston AM
    Cell Cycle; 2006 Feb; 5(3):246-9. PubMed ID: 16418579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling.
    Kolben T; Jeschke U; Reimer T; Karsten N; Schmoeckel E; Semmlinger A; Mahner S; Harbeck N; Kolben TM
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):249-256. PubMed ID: 29185091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo.
    Houston A; Waldron-Lynch FD; Bennett MW; Roche D; O'Sullivan GC; Shanahan F; O'Connell J
    Int J Cancer; 2003 Nov; 107(2):209-14. PubMed ID: 12949796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells.
    Ragnarsson GB; Mikaelsdottir EK; Vidarsson H; Jónasson JG; Olafsdóttir K; Kristjánsdóttir K; Kjartansson J; Ogmundsdóttir HM; Rafnar T
    Br J Cancer; 2000 Dec; 83(12):1715-21. PubMed ID: 11104571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obesity-Associated Myeloid-Derived Suppressor Cells Promote Apoptosis of Tumor-Infiltrating CD8 T Cells and Immunotherapy Resistance in Breast Cancer.
    Gibson JT; Orlandella RM; Turbitt WJ; Behring M; Manne U; Sorge RE; Norian LA
    Front Immunol; 2020; 11():590794. PubMed ID: 33123173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
    Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
    Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
    Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
    J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Fas/Fas ligand apoptosis pathway underlies immunomodulatory properties of human biliary tree stem/progenitor cells.
    Riccio M; Carnevale G; Cardinale V; Gibellini L; De Biasi S; Pisciotta A; Carpino G; Gentile R; Berloco PB; Brunelli R; Bastianelli C; Napoletano C; Cantafora A; Cossarizza A; Gaudio E; Alvaro D; De Pol A
    J Hepatol; 2014 Nov; 61(5):1097-105. PubMed ID: 24953023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
    Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
    Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of FasL expression in tumor cells and preventing TNF-induced apoptosis was better for immune cells survival.
    Xu G; Zhang J
    J Cancer Res Clin Oncol; 2008 Oct; 134(10):1043-9. PubMed ID: 18461366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability.
    Houston AM; Michael-Robinson JM; Walsh MD; Cummings MC; Ryan AE; Lincoln D; Pandeya N; Jass JR; Radford-Smith GL; O'Connell J
    Hum Pathol; 2008 Feb; 39(2):243-50. PubMed ID: 17961631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-existing Fas ligand (FasL) in cancer cells elicits tumor-specific protective immunity, but delayed induction of FasL expression after inoculation facilitates tumor formation.
    Chiu HY; Sun GH; Chen SY; Wang HH; Ho MY; Chu CY; Wu WL; Jhou RS; Tsai YL; Huang RT; Sun KH; Tang SJ
    Mol Carcinog; 2013 Sep; 52(9):705-14. PubMed ID: 22488710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A biochemical mechanism for resistance of intervertebral discs to metastatic cancer: Fas ligand produced by disc cells induces apoptotic cell death of cancer cells.
    Park JB; Lee JK; Cho ST; Park EY; Riew KD
    Eur Spine J; 2007 Sep; 16(9):1319-24. PubMed ID: 17684774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen.
    Mor G; Kohen F; Garcia-Velasco J; Nilsen J; Brown W; Song J; Naftolin F
    J Steroid Biochem Mol Biol; 2000; 73(5):185-94. PubMed ID: 11070347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
    Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
    Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma.
    Satchell AC; Barnetson RS; Halliday GM
    Br J Dermatol; 2004 Jul; 151(1):42-9. PubMed ID: 15270871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.